Literature DB >> 2909438

Steroid-related osteonecrosis in inflammatory bowel disease.

N Vakil1, M Sparberg.   

Abstract

Osteonecrosis is a serious complication of steroid therapy characterized by death of all the cellular elements of bone. We describe a series of patients with steroid-induced osteonecrosis in inflammatory bowel disease. Seven of 161 patients (4.3%) treated with corticosteroids for inflammatory bowel disease over a 10-yr period developed osteonecrosis. The median age at the onset of inflammatory bowel disease was 20 yr and for osteonecrosis the median age was 28 yr. Patients had received steroids for a mean duration of 42 wk with a mean daily dose of 26 mg/day and a mean cumulative lifetime prednisone dose of 7 g. Osteonecrosis occurred within 6 mo of the last administration of steroid in all patients. It presented with joint pain in the hip or knee and was frequently mistaken for the arthralgia of steroid withdrawal or the arthropathy of inflammatory bowel disease. Multiple joints were involved in 6 of the 7 patients. Surgery for the joint disease was required in 4 of the 7 patients. The median duration of follow-up was 2 yr. Five of the 7 patients continued to have significant joint pain and disability that limited their activity. We conclude that inflammatory bowel disease predisposes to steroid-induced osteonecrosis. The age of patients is younger, and the dose and duration are considerably lower than that reported for steroid-induced osteonecrosis in other disease states. Bone scans or magnetic resonance imaging should be performed in patients with joint pain who are receiving or have recently received corticosteroid therapy. Early detection and treatment may prevent the crippling long-term complications of this disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2909438     DOI: 10.1016/0016-5085(89)90764-6

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  10 in total

Review 1.  Extraintestinal manifestations of inflammatory bowel disease.

Authors:  Folashade A Jose; Melvin B Heyman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2008-02       Impact factor: 2.839

2.  Prevalence and Associations of Avascular Necrosis of the Hip in a Large Well-characterized Cohort of Patients With Inflammatory Bowel Disease.

Authors:  Vineet S Rolston; Anish V Patel; Thomas J Learch; Dalin Li; Dmitry Karayev; Chadwick Williams; Madhavi L Siddanthi; Stephan R Targan; Michael H Weisman; Dermot P B McGovern
Journal:  J Clin Rheumatol       Date:  2019-01       Impact factor: 3.517

3.  Pathophysiology and risk factors for osteonecrosis.

Authors:  Kalpit N Shah; Jennifer Racine; Lynne C Jones; Roy K Aaron
Journal:  Curr Rev Musculoskelet Med       Date:  2015-09

4.  Fluticasone propionate in Crohn's disease.

Authors:  M C de Kaski; A M Peters; J P Lavender; H J Hodgson
Journal:  Gut       Date:  1991-06       Impact factor: 23.059

5.  5-ASA Dose-Response: Maximizing Efficacy and Adherence.

Authors:  Seymour Katz; Gary R Lichtenstein; Michael A Safdi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-02

Review 6.  Comparative tolerability of treatments for inflammatory bowel disease.

Authors:  R B Stein; S B Hanauer
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

7.  Osteonecrosis of the lateral femoral condyle in a patient with ulcerative colitis: report of a case.

Authors:  Hiroaki Takeda; Shoichi Nishise; Shoichiro Fujishima; Tadahisa Fukui; Sayaka Otake; Tomohiko Orii; Takeshi Sato; Yu Sasaki; Sumio Kawata
Journal:  Clin J Gastroenterol       Date:  2008-07-12

8.  Vitamin E prevents steroid-induced osteonecrosis in rabbits.

Authors:  Masaaki Kuribayashi; Mikihiro Fujioka; Kenji A Takahashi; Yuji Arai; Masashi Ishida; Tsuyoshi Goto; Toshikazu Kubo
Journal:  Acta Orthop       Date:  2010-02       Impact factor: 3.717

9.  Autogenous osteochondral graft transplantation for steroid-induced osteonecrosis of the femoral condyle: A report of three young patients.

Authors:  Norifumi Fujita; Tomoyuki Matsumoto; Seiji Kubo; Takehiko Matsushita; Kazunari Ishida; Yuichi Hoshino; Koji Nishimoto; Masahiro Kurosaka; Ryosuke Kuroda
Journal:  Sports Med Arthrosc Rehabil Ther Technol       Date:  2012-04-26

10.  Long-interval Cytapheresis as a Novel Therapeutic Strategy Leading to Dosage Reduction and Discontinuation of Steroids in Steroid-dependent Ulcerative Colitis.

Authors:  Masahiro Iizuka; Takeshi Etou; Makoto Kumagai; Atsushi Matsuoka; Yuka Numata; Shiho Sagara
Journal:  Intern Med       Date:  2017-09-15       Impact factor: 1.271

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.